Table 3.

RAPID-PsA: improvements in productivity in the workplace and within the home at week 24 (RS population, LOCF)

	Placebo	CZP 200 mg Q2W	CZP 400 mg Q4W	CZP 200 mg – Placebo Mean diff (95% CI) (p value)	CZP 400 mg – Placebo Mean diff (95% CI) (p value)
	Mean
Productivity at the workplace over previous month (employed patients only)	n=76	n=84	n=84
Work days missed due to arthritis	1.6	0.2	0.6	−1.4 (−3.4 to −0.6) (<0.001)	−1.0 (−2.8 to −0.1) (0.060)
Days with work productivity reduced by ≥50% due to arthritis*	3.5	1.3	2.1	−2.2 (−4.1 to −0.7) (0.003)	−1.4 (−3.4 to 0.6) (0.176)
Rate of arthritis interference with work productivity†	3.2	1.7	1.9	−1.4 (−2.3 to −0.7) (<0.001)	−1.2 (−2.1 to −0.4) (0.004)
Productivity at home and daily activities over previous month	n=136	n=138	n=135
Days with no household work due to arthritis	4.7	2.5	2.4	−2.3 (−4.0 to −0.7) (0.007)	−2.2 (−3.9 to −0.6) (0.010)
Days with household work productivity reduced by ≥50% due to arthritis*	6.8	2.9	3.5	−3.9 (−5.8 to −2.2) (<0.001)	−3.4 (−5.3 to −1.5) (<0.001)
Days missed of family, social or leisure activities due to arthritis	2.8	1.1	1.0	−1.7 (−3.1 to −0.5) (0.005)	−1.8 (−3.2 to −0.6) (0.004)
Days with outside help hired due to arthritis	1.9	0.7	1.5	−1.2 (−2.4 to −0.3) (0.008)	−0.4 (−1.7 to 1.0) (0.582)
Rate of arthritis interference with household work productivity†	4.1	2.2	2.6	−1.8 (−2.5 to −1.2) (<0.001)	−1.5 (−2.1 to −0.8) (<0.001)

*Does not include days counted in the previous question, ‘Work days missed due to arthritis’.

†0–10 scale, where 0=no interference, 10=complete interference.

CZP, certolizumab pegol; LOCF, last observation carried forward; Q2W, every 2 weeks; Q4W, every 4 weeks; RS, randomised set.